2021 Year End Report
2021 Year End Report Each quarter, Locust Walk deal team members compile key statistics and trends on strategic transactions and financings. Our 2021 […]
2021 Year End Report Each quarter, Locust Walk deal team members compile key statistics and trends on strategic transactions and financings. Our 2021 […]
Bought Not Sold Why So Many Biopharma M&A Transactions Start Out as Aspirational Licensing Deals Authors: Geoff Meyerson, CEO & Co-Founder
2021 Q3 Report: Global Trends in Biopharma Transactions Each quarter, Locust Walk deal team members compile key statistics and trends on
Crossover Evolution: The Evolving Role of the Crossover Financing Round Authors: Geoff Meyerson, CEO & Co-Founder Brian Coleman, Global Head of Capital
2021 Q1 Report: Global Trends in Biopharma Transactions Each quarter, Locust Walk deal team members compile key statistics and trends on
Locust Walk 2020 Year End Report Each quarter our team at Locust Walk compiles key statistics and trends on strategic
Doubling Down Following up on our recent white paper, Biopharma’s COVID Capital Comeback, here is a look at the greatest risk
Q3 2020 Report: Global Trends in Biopharma Transactions Each quarter our team at Locust Walk compiles key statistics and trends on strategic
Biopharma’s COVID Capital Comeback What a difference a few months can make – especially during a pandemic. Heading into 2020,
SUBSCRIBE TO OUR INSIGHTS Linkedin Twitter Youtube Instagram CATEGORIES Asian Capabilities Capital Raising Commercial Assessment Locust Walk Institute Market Trends